About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New, Effective Sleeping Pill from Merck to Hit US Markets

by Thilaka Ravi on May 22, 2013 at 10:15 AM
Font : A-A+

New, Effective Sleeping Pill from Merck to Hit US Markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall asleep and stay asleep, say reviewers at the US Food and Drug Administration, which could soon approve the new drug.

But the experts warned of dangerous side effects at high doses -- including residual sleepiness during the day and, in a small number of subjects, suicidal thoughts -- according to their report posted Tuesday.

Advertisement

The FDA has convened a group of independent experts for Wednesday to make recommendations to the agency on whether to authorize the medication for the US market.

The FDA is not required to follow the recommendations of the panel, but generally does so.

The drug, Suvorexant, also known as MK-4305, is a new class of sleeping pill, which works by blocking "wakefulness-promoting orexin neurons" from working, thus helping the body transition to sleep.
Advertisement

Merck has proposed a dose of 15 milligrams for people over 65 and 20 milligrams for those under 65, with doses up to twice as high recommended for those whose symptoms persist.

But the FDA noted clinical trials indicated a dose of just 10 milligrams was safe and effective, and it planned to ask the independent panel to consider recommending all patients start with this smaller dose and whether it should ask Merck to study if doses under 10 milligrams might also be effective.

In January, the FDA asked the pharmaceutical companies behind Ambien and other similar sleep aids to reduce their recommended dosages after studies showed an increased risk of daytime sleepiness and related car accidents.

The FDA notably required the companies to cut by half the recommended doses for some sleeping pills for women -- whose bodies apparently metabolize the drugs more slowly.

Insomnia affects up to 30 percent of US adults, the FDA said.

According to analysts, Suvorexant could generate for Merck some $650 million in sales by 2018.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Guide to Brushing Your Teeth the Right Way
Resting Heart Rate
Is COVID-19 Vaccination during Pregnancy Safe?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Vasectomy Insomnia Top Ten Selling Drugs Sleeping Scale 

Recommended Reading
Insomnia
Difficulty in initiating and maintaining sleep is known as insomnia. It is a symptom that occurs ......
Sleep Disorder
Sleep disorders can either be having difficulty in getting sleep or dozing off at inappropriate ......
Sleep Disturbances In Women
The physical, emotional and hormonal changes that occur in women during puberty, menstrual cycle, .....
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use